Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumefantrine + amodiaquine + primaquine
- Development stage
- Unknown
- Lead developer
- Mahidol Oxford Tropical Medicine Research Unit
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Artemether-lumefantrine + amodiaquine + primaquine is an investigational triple artemisinin-based combination therapy (TACT) being developed for the treatment of uncomplicated *Plasmodium falciparum* malaria. This combination aims to combat multidrug-resistant malaria by combining a standard fixed-dose artemisinin-based combination therapy (ACT), artemether-lumefantrine, with a third long-acting partner drug, amodiaquine, and the gametocytocidal agent primaquine. Artemether and amodiaquine act on the asexual blood stages of the parasite by inhibiting heme detoxification and generating cytotoxic free radicals, while primaquine targets gametocytes to reduce malaria transmission. The combination is being studied by the University of Oxford in collaboration with Mahidol University to evaluate pharmacokinetic interactions and safety.
- Other names
- Triple artemisinin-based combination therapyTACT
02
Targets
Heme
Beyond the preview
Go deeper on artemether + lumefantrine + amodiaquine + primaquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumefantrine + amodiaquine + primaquine.